Efficacy of PEEK Acuity Versus ETDRS Chart for Assessment of Visual Acuity and Refractive Error
1 other identifier
observational
51
1 country
1
Brief Summary
Visual acuity is a key indicator of visual function, often measured using the ETDRS chart, the gold standard in clinical settings. However, the increasing need for accessible and cost-effective screening tools, especially in underserved areas, has led to the development of mobile health applications like the Peek Acuity application.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Mar 2025
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 20, 2025
CompletedFirst Submitted
Initial submission to the registry
March 29, 2025
CompletedFirst Posted
Study publicly available on registry
April 6, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 20, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
February 20, 2026
CompletedApril 6, 2025
March 1, 2025
3 months
March 29, 2025
March 29, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Peek Acuity
Peek Acuity is easier to administer than an equivalent wall chart, such as Snellen or ETDRS, and is generally quicker to complete. The algorithm that controls progress through each test is optimised for clinical accuracy, so the test will end just as soon as a reliable score has been obtained.
12 Months
Eligibility Criteria
Visual acuity is a key indicator of visual function, often measured using the ETDRS chart, the gold standard in clinical settings. However, the increasing need for accessible and cost-effective screening tools, especially in underserved areas,
You may qualify if:
- Males and females.
- years of age or older.
- Individuals with normal vision or those with refractive error who had their corrected glasses.
- Individuals who are willing and able to provide written informed consent to participate in the study.
You may not qualify if:
- Individuals with anterior segment abnormalities such as conjunctivitis, Iritis, uveitis, keratitis, or corneal ulcers.
- Individuals with vision deprivation due to corneal opacities, cataracts, glaucoma, retinal, and optic nerve pathologies.
- Postoperative/intraoperative complications.
- Have received mydriatic drops.
- Individuals who cannot achieve normal visual acuity with corrective lenses (glasses or contact lenses).
- Individuals with neurological conditions affecting vision
- Individuals unable to cooperate with visual acuity testing due to cognitive impairments or language barriers.
- Individuals who have had refractive surgery or other eye treatments within the past 6 months.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Eagle Eyes Relief Trust FF120, Divine mega 2, new airport road
Lahore, Punjab Province, Pakistan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
March 29, 2025
First Posted
April 6, 2025
Study Start
March 20, 2025
Primary Completion
June 20, 2025
Study Completion
February 20, 2026
Last Updated
April 6, 2025
Record last verified: 2025-03
Data Sharing
- IPD Sharing
- Will not share